BioWorld

Jan. 8, 2007

Most Signals Suggest A Positive 2007 For Biotech

A number of signs point to some promising new and continuing trends for the biotech industry in the year ahead, observers are saying, with myriad financial opportunities available to companies and investors alike. (BioWorld Today) Read More

Despite Decades Of Change, Industry Tradition Carries On

Sequoia's $35M Series C To Support Two Clinical Trials

OSI, Lilly Sign Potential $385M Deal For GKA Drugs In Diabetes

Clinic Roundup

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 11, 2025.

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

BioWorld

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...

Corestemchemon preps US BLA filing for stem cell ALS therapy

BioWorld Asia

Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...

Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

BioWorld

With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...